The agreement had been announced on December 13, 2022: “Takeda to Acquire 100% Ownership of Nimbus Therapeutics’ TYK2 Program Subsidiary”. Important NoticeFor the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this press release. No shares or other securities are being offered to the public by means of this press release. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Takeda does not undertake to update any of the forward-looking statements contained in this report or any other forward-looking statements it may make, except as required by law or stock exchange rule.
As the flagship event of Life Science Integrates’ calendar, Pharma Integrates saw the brightest minds from industry, academia, policy, and practice gather to discuss the biggest issues of today. A full event summary and video recordings are available on the Life Science Integrates website, where details of 2023 events will be released shortly. ENDSNotes to EditorsAbout Life Science IntegratesLSI creates strategy-led life science conferences that enable the achievement of business and commercial goals. We create communities of shared commercial and scientific interest for life science leaders based on sustainable relationships of trust, knowledge and understanding. Our primary audiences are life science leaders operating at C-Suite level, as well as those responsible for strategy, business and science.3 months ago PharmiWeb.com
Psoriasis is also associated with serious mental health conditions. “The goal for World Psoriasis Day 2022 is to raise awareness between psoriatic disease and mental health. “The link between psoriasis and the impact on mental health is well documented. [xi] Canadian Psoriasis Network, Canadian Association of Psoriasis Patients & Unmasking Psoriasis. Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003-2011.4 months ago PharmiWeb.com
LUXEMBOURG--(BUSINESS WIRE)--Regulatory News:Eurofins (Paris:ERF):To mark World Soil Day (December 5th), Eurofins Agro Testing announces the launch of Soil Carbon Check as part of Soil Health Solutions, a new suite of testing solutions that will support the agricultural sector to transition to more sustainable farming practices. The Soil Carbon Check test will provide insights into the levels of carbon storage in fields, which supports the reduction of CO 2 in the atmosphere. Data garnered through the Soil Carbon Check test reports can be used to support sustainability claims and carbon credits, as proof of sustainable farming and as credentials for other partners in the agri-food chain. Soil Carbon Check provides customers with information on how much carbon is sequestered in their soil, how stable their soil carbon is and how it can be improved, and tracks how the carbon content of soil changes over time. In addition to Soil Carbon Check, the suite of tests offered by Soil Health Solutions provide insights into physical soil health (supporting the efficient use of water), potential contaminants in soil, biological soil health (to determine the biodiversity status of soil and effective actions to regenerate it) and chemical soil health (to prevent yield gaps and improve food quality).3 months ago PharmiWeb.com
Moderna and CytomX will collaborate on discovery and pre-clinical development and Moderna will lead clinical development and commercialization of therapeutics resulting from the agreement. About CytomX Therapeutics, Inc.CytomX is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. These forward-looking statements are based on Moderna's current expectations and speak only as of the date hereof. CytomX Forward-Looking StatementsThis press release includes forward-looking statements. Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.2 months ago PharmiWeb.com
Pandemic Antiviral Discovery (PAD) makes first investments to support the development of new antiviral medicines for future pandemicsFourteen research projects will focus on antiviral research and drug development for henipaviruses, a subgroup of viruses with pandemic potential. Today, the partners in Pandemic Antiviral Discovery (PAD) initiative announced grants totalling more than USD 26 million for 14 research projects aimed at facilitating early-stage development of drugs to treat henipavirus infection and disease in humans. Its purpose is to accelerate the discovery and development of antiviral drugs for future pandemic threats. With equitable access as a core principle of the initiative, PAD is focused on ensuring these interventions are accessible to people in low- and middle-income countries. About the PAD initiativePandemic Antiviral Discovery (PAD) is a global philanthropic initiative launched by the Bill & Melinda Gates Foundation, Open Philanthropy, and the Novo Nordisk Foundation.29 days ago PharmiWeb.com